Product information and disease descriptionProduct descriptionProduct information
Access and distribution
1 evidence topic · 1 source
Summary: access during development
Emiltatug ledadotin is available only within the NCT05377996 phase 1/2 trial, which the registry lists as recruiting, with an estimated enrollment of 360 participants aged 18 years or older. The registry record indicates that expanded access is not available. No commercial distribution model, specialty pharmacy arrangement, or site-of-care restriction has been described.
Expanded access program
No evidence found.
Distribution channel and specialty pharmacy arrangements
No evidence found.